Human papillomavirus (HPV) related oropharyngeal squamous cell carcinoma (OPSCC) is associated with improved outcomes compared to non-virally mediated disease. Clinical trials are actively investigating de-escalation strategies to maintain excellent survival outcomes while minimizing toxicity. Delivery of effective precision medicine-based therapeutic approaches are strengthened by the identification of biomarkers to predict treatment response. Plasma circulating tumor (ct) DNA is the most studied liquid biomarker in head and neck cancer and has shown great promise in the ability to determine treatment response and monitor for disease recurrence. In this review, we examine the emerging evidence for ctDNA as a biomarker in HPV related OPSCC and discuss opportunities for future investigation and integration into clinical practice.
Keywords: Biomarker based clinical trials; Circulating tumor DNA (ctDNA); Cost analysis of ctDNA; Detection of minimal residual disease with ctDNA; Head and neck cancer; Human papillomavirus (HPV); Liquid biomarkers; Oropharynx squamous cell carcinoma; Predictive biomarkers; Prognostic biomarkers.
Copyright © 2022 Elsevier Ltd. All rights reserved.